The goal of Project 5 is to investigate the control of apolipoprotein E (apoE) gene expression in macrophages, the role of macrophage apoE in cellular cholesterol metabolism, and macrophage functions which play a role in atherosclerotic lesion formation and progression. The experimental approach to these issues will make extensive use of the trangenic core, creating new transgenic and targeted deletion mice as well as breeding with existing transgenic and gene knockout strains.
The specific aims of this project are 1) to determine the DNA elements and trans-acting factors which control the tissue specific and cholesterol regulated expression of apoE in macrophages; 2) to characterize the role and mechanism of macrophage apoE in promoting macrophage cholesterol efflux and in preventing atherosclerosis; and 3) to develop animal models to gain insight into the mechanisms of macrophage involvement in atherosclerosis by breeding atherosclerosis-prone apoE deficient mice with other mutant or transgenic strains which disrupt macrophage development or functions. This project is directly related to the central theme of the program, namely the investigation of lipid and lipoprotein metabolism and atherogenesis using cell cultaure models and genetically manipulated mice. The analysis of macrophage apoE gene expression may yield novel information about macrophage specific regulatory elements and the mechanism of cholesterol up-regulation of gene expression. Understanding the role of macrophage apoE in cholesterol efflux and which macrophage functions are involved in atherosclerosis may be of significance in developing strategies to prevent atherogenesis and lesion progression.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL054591-03
Application #
6242497
Study Section
Project Start
1997-07-01
Project End
1998-06-30
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Rockefeller University
Department
Type
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Fredman, Gabrielle; Kamaly, Nazila; Spolitu, Stefano et al. (2015) Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7:275ra20
Libby, Peter; Tabas, Ira; Fredman, Gabrielle et al. (2014) Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 114:1867-79
Subramanian, Manikandan; Tabas, Ira (2014) Dendritic cells in atherosclerosis. Semin Immunopathol 36:93-102
Subramanian, Manikandan; Hayes, Crystal D; Thome, Joseph J et al. (2014) An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J Clin Invest 124:1296-308
Nagareddy, Prabhakara R; Murphy, Andrew J; Stirzaker, Roslynn A et al. (2013) Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 17:695-708
Subramanian, Manikandan; Thorp, Edward; Hansson, Goran K et al. (2013) Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest 123:179-88
Gautier, Emmanuel L; Westerterp, Marit; Bhagwat, Neha et al. (2013) HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 210:339-53
Rodríguez, José M; Wolfrum, Susanne; Robblee, Megan et al. (2013) Altered expression of Raet1e, a major histocompatibility complex class 1-like molecule, underlies the atherosclerosis modifier locus Ath11 10b. Circ Res 113:1054-64
Tabas, Ira; Glass, Christopher K (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339:166-72
Rong, James X; Blachford, Courtney; Feig, Jonathan E et al. (2013) ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Arterioscler Thromb Vasc Biol 33:4-12

Showing the most recent 10 out of 124 publications